Printer Friendly

CYTOGEN ANNOUNCES APPOINTMENT OF JAMES R. KNILL, M.D., AS V.P. OF MEDICAL AFFAIRS

 PRINCETON, N.J., Jan. 5 /PRNewswire/ -- CYTOGEN Corporation (NASDAQ: CYTO) announced today that Dr. James R. Knill has joined the company as vice president, Medical Affairs, with responsibility for Pre-Clinical Research, Clinical Investigations, Regulatory Sciences and Medical Affairs.
 Dr. Knill has more than 25 years experience in the pharmaceutical industry, including management of drug discovery, clinical research, product development and strategic planning. For the past five years, he has served as Senior Advisor to Bristol-Myers Squibb Research Institute. Prior to that time, Dr. Knill was senior vice president of Science Strategy and Planning of Squibb Corporation.
 While at Squibb, Dr. Knill was instrumental in the implementation of single-standard, high quality clinical research programs worldwide, that met all national regulatory requirements and, subsequently, along with creative planning on a country by country basis, reduced development time by 50 percent over the generally accepted norm. This program also provided published scientific data bases for successful marketing of products, and the integration of government and academic interactions into new drug development.
 Commenting on the appointment, CYTOGEN's President, Dr. Thomas J. McKearn stated, "Dr. Knill's extensive clinical and regulatory experience will play an instrumental part in CYTOGEN's continued progress towards becoming a leader in cancer care. He provides us with the broad range of skills and experience needed to bring additional pharmaceutical products to the market in a timely and cost-conscious manner."
 Dr. Knill holds an M.D. degree and a M.Sc. degree from the University of Western Ontario, London, Ontario and received his M.B.A. from The Wharton School, University of Pennsylvania.
 CYTOGEN is a biopharmaceutical company engaged in the marketing and development of products for the targeted delivery of diagnostic and therapeutic substances directly to sites of disease. CYTOGEN uses its patented and proprietary antibody "linker" technology primarily to develop specific cancer diagnostic imaging and cancer therapeutic products.
 /delval/
 -0- 1/5/93
 /CONTACT: Colleen P. Teschko, Corporate Communications of CYTOGEN, 609-987-8221/
 (CYTO)


CO: Cytogen Corporation ST: New Jersey IN: MTC SU: PER

MK -- PH018 -- 9403 01/05/94 14:34 EST
COPYRIGHT 1994 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1994 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jan 5, 1994
Words:342
Previous Article:SPS TECHNOLOGIES TO REDUCE NON-DIRECT EMPLOYMENT 10 PERCENT, RECORD FOURTH QUARTER RESTRUCTURING CHARGE
Next Article:PHOENIX NEWSPAPERS INC. LEADS INDUSTRY IN CREATING TECHNOLOGY POSITION
Topics:

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters